Association between age at diagnosis and degree of liver injury in hepatitis C

Estudo de Prevalência de Base Populacional das Infecções pelos vírus das Hepatites A, B e C nas capitais do Brasil – Ministério da Saúde 2010.

Instituto Brasileiro de Geografia e Estatística. Censo 2010 em http://www.censo2010.ibge.gov.br/resultados.

Pesquisa sobre Hepatite C – Sociedade Brasileira de Hepatologia, Data Folha 2011 em www.sbhepatologia.org.br/pdf/release2.pdf, acessado em 09/10/2013.

Políticas de Prevenção, Assistência e Tratamento das Hepatites Virais, Departamento de DST, Aids e Hepatites Virais, Secretaria de Vigilância em Saúde, Brasília, 7 de agosto de 2012. http://www.aids.gov.br/sites/default/files/anexos/page/2010/380/112_cnaids_07ago12_apresentacao_hepatites_fina_27592.pdf.

Oliveira, 2013, Esteatose na doença hepática alcoólica e na hepatite pelo vírus C, 61

Carrilho, 2010, Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil, Clinics (São Paulo), 65, 1285, 10.1590/S1807-59322010001200010

Salvalaggio, 2012, The MELD system and liver transplant waiting-list mortality in developing countries: lessons learned from São Paulo, Brazil, Einstein (Sao Paulo), 10, 278, 10.1590/S1679-45082012000300004

Bedossa, 1996, An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group, Hepatology, 24, 289, 10.1002/hep.510240201

Focaccia, 1998, Estimated prevalence of viral hepatitis in the general population of the Municipality of São Paulo, Measured by a Serologic Survey of a Stratified, Randomized and Residence-Based Population, Braz J Infect Dis, 2, 269

SINAM. Boletim de Hepatites – casos notificados. In: www.aids.gov.br/sites/defaut/ boletim hepatitis; 2011.

Vasconcelos, 2006, Fatores associados às formas evolutivas graves da infecção crônica pelo vírus da hepatite C, Rev Soc Bras Med Trop, 39, 433, 10.1590/S0037-86822006000500003

Costa, 2002, Effect of host-related factors on the intensity of liver fibrosis in patients with chronic hepatitis C vírus infection, Braz J Infect Dis, 6, 219, 10.1590/S1413-86702002000500002

Poynard, 1997, Natural history of liver fibrosis progression in patients with chronic hepatitis C, Lancet, 349, 825, 10.1016/S0140-6736(96)07642-8

Poynard, 2001, Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C, J Hepatol, 34, 764, 10.1016/S0168-8278(00)00097-0

Williams, 2011, Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection, J Viral Hep, 18, 17, 10.1111/j.1365-2893.2009.01262.x

McGarry, 2012, Economic model of a birth cohort screening program for hepatitis C virus, Hepatology, 55, 1344, 10.1002/hep.25510

Coffin, 2012, Cost-effectiveness and population outcomes of general population screening for hepatitis C, Clin Infect Dis, 54, 1259, 10.1093/cid/cis011

Bourlière, 2012, Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003–2007), Antivir Ther, 17, 101, 10.3851/IMP1935

Parise, 2006, Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis, Braz J Infect Dis, 10, 78, 10.1590/S1413-86702006000200002

Everson, 2006, Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial, Hepatology, 44, 1675, 10.1002/hep.21440

Poynard, 1997, Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups, Lancet, 349, 825, 10.1016/S0140-6736(96)07642-8

Nousbaum, 1995, Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group, Ann Intern Med, 122, 161, 10.7326/0003-4819-122-3-199502010-00001

Zein, 1996, Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group, Ann Intern Med, 125, 634, 10.7326/0003-4819-125-8-199610150-00002